PEMBROLIZUMAB

Information current as at:

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Keytruda®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Merck Sharp & Dohme (Australia) Pty Ltd
Condition/indication:
(therapeutic use)
  • Gastro-oesophageal cancers
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Matters Outstanding (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
May 2022 PBAC meeting
Opportunity for consumer comment:
Open 24/11/2021 and close 27/01/2022 (see PBS Website)
PBAC meeting:
Held on 06/05/2022
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – May 2022
Case ID
a565
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19